Compare Stocks: ANNX, VCYT, ABCL, and CLDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$11.38 +3.7%	$6.65	$2.74 ▼ $11.50	$3.49B	1.2	8.99 million shs	12.33 million shs
ANNX Annexon	$5.29 +0.6%	$5.35	$2.03 ▼ $7.18	$1.00B	1.18	2.51 million shs	2.99 million shs
CLDX Celldex Therapeutics	$41.95 -1.5%	$36.58	$20.37 ▼ $45.14	$3.29B	0.87	1.01 million shs	849,360 shs
VCYT Veracyte	$41.25 -3.2%	$53.33	$28.25 ▼ $60.91	$3.32B	1.95	1.36 million shs	1.67 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	+64.21%	+84.74%	+178.24%	+148.69%
ANNX Annexon	0.00%	-2.22%	-10.19%	+1.54%	+103.46%
CLDX Celldex Therapeutics	0.00%	+0.58%	+18.50%	+33.85%	+67.87%
VCYT Veracyte	0.00%	-12.64%	-30.34%	+7.20%	+34.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$11.38 +3.7%	$6.65	$2.74 ▼ $11.50	$3.49B	1.2	8.99 million shs	12.33 million shs
ANNX Annexon	$5.29 +0.6%	$5.35	$2.03 ▼ $7.18	$1.00B	1.18	2.51 million shs	2.99 million shs
CLDX Celldex Therapeutics	$41.95 -1.5%	$36.58	$20.37 ▼ $45.14	$3.29B	0.87	1.01 million shs	849,360 shs
VCYT Veracyte	$41.25 -3.2%	$53.33	$28.25 ▼ $60.91	$3.32B	1.95	1.36 million shs	1.67 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	+64.21%	+84.74%	+178.24%	+148.69%
ANNX Annexon	0.00%	-2.22%	-10.19%	+1.54%	+103.46%
CLDX Celldex Therapeutics	0.00%	+0.58%	+18.50%	+33.85%	+67.87%
VCYT Veracyte	0.00%	-12.64%	-30.34%	+7.20%	+34.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.71	Moderate Buy	$12.83	12.77% Upside
ANNX Annexon	2.30	Hold	$15.33	189.86% Upside
CLDX Celldex Therapeutics	2.86	Moderate Buy	$55.46	32.21% Upside
VCYT Veracyte	2.82	Moderate Buy	$54.33	31.72% Upside

Current Analyst Ratings Breakdown

Latest ANNX, VCYT, ABCL, and CLDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	ANNX Annexon	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform
8/11/2026	ABCL AbCellera Biologics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$12.00 ➝ $30.00
8/11/2026	VCYT Veracyte	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/7/2026	VCYT Veracyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/7/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$40.00 ➝ $46.00
8/7/2026	CLDX Celldex Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $53.00
8/6/2026	ABCL AbCellera Biologics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $9.00
8/6/2026	ABCL AbCellera Biologics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$11.00 ➝ $12.00
8/4/2026	VCYT Veracyte	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$66.00 ➝ $54.00
8/4/2026	VCYT Veracyte	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$68.00 ➝ $55.00
8/4/2026	VCYT Veracyte	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underweight	$47.00 ➝ $44.00

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$75.13M	46.44	N/A	N/A	$2.92 per share	3.90
ANNX Annexon	N/A	N/A	N/A	N/A	$0.98 per share	N/A
CLDX Celldex Therapeutics	$1.54M	2,139.18	N/A	N/A	$9.10 per share	4.61
VCYT Veracyte	$517.15M	6.41	$1.49 per share	27.69	$17.27 per share	2.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.41M	-$0.54	N/A	N/A	N/A	-248.83%	-17.49%	-12.36%	N/A
ANNX Annexon	-$206.69M	-$1.16	N/A	N/A	N/A	N/A	-106.15%	-79.82%	N/A
CLDX Celldex Therapeutics	-$258.76M	-$4.35	N/A	N/A	N/A	N/A	-52.35%	-47.61%	N/A
VCYT Veracyte	$66.35M	$1.41	29.26	26.79	N/A	20.37%	9.26%	8.61%	11/3/2026 (Estimated)

Latest ANNX, VCYT, ABCL, and CLDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ANNX Annexon	-$0.2388	-$0.28	-$0.0412	-$0.28	$6.50 million	N/A
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1640	-$0.18	-$0.0160	-$0.18	$7.85 million	$4.05 million
7/30/2026	Q2 2026	VCYT Veracyte	$0.4103	$0.54	+$0.1297	$0.31	$144.59 million	$150.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	12.77	12.77
ANNX Annexon	N/A	5.53	6.35
CLDX Celldex Therapeutics	N/A	11.82	11.82
VCYT Veracyte	N/A	9.16	8.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
ANNX Annexon	N/A
CLDX Celldex Therapeutics	N/A
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.40%
ANNX Annexon	10.31%
CLDX Celldex Therapeutics	5.20%
VCYT Veracyte	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	306.61 million	219.53 million	Optionable
ANNX Annexon	60	189.58 million	170.03 million	Optionable
CLDX Celldex Therapeutics	150	78.53 million	74.45 million	Optionable
VCYT Veracyte	790	80.39 million	79.11 million	Optionable

ANNX, VCYT, ABCL, and CLDX Headlines

Recent News About These Companies

Zacks Research Upgrades Veracyte (NASDAQ:VCYT) to Strong-Buy

August 13 at 7:35 AM | marketbeat.com

Bank of America Corp DE Grows Stock Position in Veracyte, Inc. $VCYT

August 13 at 3:23 AM | marketbeat.com

Amundi Sells 116,588 Shares of Veracyte, Inc. $VCYT

August 12, 2026 | marketbeat.com

Veracyte: Diagnostics With Favorable Economics

August 10, 2026 | seekingalpha.com

Veracyte: Core Growth Funds Prosigna And TrueMRD

August 9, 2026 | seekingalpha.com

Royal Bank of Canada Grows Stock Holdings in Veracyte, Inc. $VCYT

August 7, 2026 | marketbeat.com

Veracyte, Inc. $VCYT Shares Sold by Janus Henderson Group PLC

August 7, 2026 | marketbeat.com

Veracyte (NASDAQ:VCYT) Growth Story Gains Fresh Market Attention

August 6, 2026 | kalkinemedia.comK

Empowered Funds LLC Buys 68,171 Shares of Veracyte, Inc. $VCYT

August 6, 2026 | marketbeat.com

Morgan Stanley Has Lowered Expectations for Veracyte (NASDAQ:VCYT) Stock Price

August 6, 2026 | americanbankingnews.com

Renaissance Technologies LLC Takes Position in Veracyte, Inc. $VCYT

August 5, 2026 | marketbeat.com

Guggenheim Reaffirms Their Buy Rating on Veracyte (VCYT)

August 4, 2026 | theglobeandmail.com

Stephens Issues Pessimistic Forecast for Veracyte (NASDAQ:VCYT) Stock Price

August 4, 2026 | marketbeat.com

Veracyte (NASDAQ:VCYT) Price Target Cut to $44.00 by Analysts at Morgan Stanley

August 4, 2026 | marketbeat.com

Arrowstreet Capital Limited Partnership Takes Position in Veracyte, Inc. $VCYT

August 4, 2026 | marketbeat.com

Veracyte Q2 Earnings Call Highlights

July 31, 2026 | marketbeat.com

Veracyte (NASDAQ:VCYT) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS

July 31, 2026 | marketbeat.com

Veracyte (NASDAQ:VCYT) Shares Gap Down - Here's What Happened

July 31, 2026 | marketbeat.com

Is Veracyte (VCYT) Fully Valued After Raising 2026 Revenue Guidance?

July 31, 2026 | finance.yahoo.com

Veracyte Q2 Non-GAAP Earnings, Revenue Rise; 2026 Revenue Guidance Raised

July 31, 2026 | finance.yahoo.com

Veracyte, Inc. 2026 Q2 - Results - Earnings Call Presentation

July 31, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX, VCYT, ABCL, and CLDX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$11.38 +0.41 (+3.74%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$11.40 +0.02 (+0.18%)

As of 08/14/2026 07:59 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Annexon NASDAQ:ANNX

$5.29 +0.03 (+0.57%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$5.50 +0.21 (+3.97%)

As of 08/14/2026 07:56 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Celldex Therapeutics NASDAQ:CLDX

$41.95 -0.66 (-1.55%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$41.94 -0.02 (-0.04%)

As of 08/14/2026 07:34 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Veracyte NASDAQ:VCYT

$41.25 -1.35 (-3.17%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$41.79 +0.54 (+1.31%)

As of 08/14/2026 07:59 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANNX, VCYT, ABCL, and CLDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANNX, VCYT, ABCL, and CLDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANNX, VCYT, ABCL, and CLDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX, VCYT, ABCL, and CLDX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Annexon NASDAQ:ANNX

Celldex Therapeutics NASDAQ:CLDX

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANNX, VCYT, ABCL, and CLDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANNX, VCYT, ABCL, and CLDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANNX, VCYT, ABCL, and CLDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX, VCYT, ABCL, and CLDX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Annexon NASDAQ:ANNX

Celldex Therapeutics NASDAQ:CLDX

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools